Corvus Pharma Com (CRVS)

Jun 9, 2026, 7:30 AM EDT - 5 days ago

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Jun 8, 2026, 11:20 AM EDT - 6 days ago

Corvus Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 3:45 PM EDT - 11 days ago

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 3:45 PM EDT - 11 days ago

Corvus Pharmaceuticals Slides: FY 2026

May 20, 2026, 4:01 PM EDT - 25 days ago

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

May 14, 2026, 1:30 PM EDT - 4 weeks ago

Corvus Pharmaceuticals Transcript: Study update

May 14, 2026, 1:30 PM EDT - 4 weeks ago

Corvus Pharmaceuticals Press release: Study update

May 14, 2026, 1:30 PM EDT - 4 weeks ago

Corvus Pharmaceuticals Slides: Study update

May 14, 2026, 7:00 AM EDT - 4 weeks ago

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

SID

2026-05-07T21:26:08.000Z - 5 weeks ago

Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

May 7, 2026, 4:01 PM EDT - 5 weeks ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 4:00 PM EDT - 5 weeks ago

Corvus Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 5 weeks ago

Corvus Pharmaceuticals Quarterly report: Q1 2026

Apr 24, 2026, 8:00 AM EDT - 7 weeks ago

Corvus Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 7 weeks ago

Corvus Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 7:30 AM EDT - 7 weeks ago

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

Apr 21, 2026, 7:30 AM EDT - 7 weeks ago

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

2026-04-17T08:45:23.000Z - 2 months ago

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

2026-03-13T12:16:32.000Z - 3 months ago

Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

2026-03-13T12:08:45.000Z - 3 months ago

Corvus Pharmaceuticals files automatic mixed securities shelf

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Corvus Pharmaceuticals Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Corvus Pharmaceuticals Earnings release: Q4 2025

2026-03-12T20:05:16.000Z - 3 months ago

Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

Mar 12, 2026, 4:01 PM EDT - 3 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 12, 2026, 4:00 PM EDT - 3 months ago

Corvus Pharmaceuticals Slides: Corporate presentation

Mar 5, 2026, 4:01 PM EST - 3 months ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Feb 26, 2026, 2:40 PM EST - 3 months ago

Corvus Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 7:00 AM EST - 3 months ago

Corvus Pharmaceuticals Slides: Corporate presentation

Feb 23, 2026, 4:01 PM EST - 3 months ago

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-29T11:51:48.000Z - 4 months ago

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

Jan 23, 2026, 5:00 PM EST - 5 months ago

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

2026-01-22T17:30:16.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies

2026-01-22T13:40:42.000Z - 5 months ago

Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15

Jan 21, 2026, 10:53 PM EST - 5 months ago

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

2026-01-21T13:50:38.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer

2026-01-20T21:10:39.000Z - 5 months ago

Corvus Pharmaceuticals announces $150M common stock offering

Jan 20, 2026, 4:01 PM EST - 5 months ago

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-01-20T20:30:11.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays

Jan 20, 2026, 2:10 PM EST - 5 months ago

What made Corvus stock double on Tuesday and is it sustainable?

2026-01-20T17:35:42.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho

2026-01-20T16:05:45.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright

Jan 20, 2026, 8:00 AM EST - 5 months ago

Corvus Pharmaceuticals Transcript: Study result

Jan 20, 2026, 8:00 AM EST - 5 months ago

Corvus Pharmaceuticals Press release: Study result

Jan 20, 2026, 8:00 AM EST - 5 months ago

Corvus Pharmaceuticals Slides: Study result

Jan 16, 2026, 4:01 PM EST - 5 months ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Nov 10, 2025, 8:30 AM EST - 7 months ago

Corvus Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 4:30 PM EST - 7 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Corvus Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Corvus Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 7 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:00 PM EST - 7 months ago

Corvus Pharmaceuticals Slides: Corporate Presentation

Oct 31, 2025, 7:30 AM EDT - 8 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 28, 2025, 4:01 PM EDT - 8 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 17, 2025, 10:00 AM EDT - 8 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 2, 2025, 4:01 PM EDT - 9 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Corvus Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Corvus Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Jun 5, 2025, 9:20 AM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Slides: Corporate Presentation

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 28, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Slides: Q1 2025

May 8, 2025, 4:02 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 4:08 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 9, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Mar 27, 2025, 12:00 PM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Annual report: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings release: Q4 2024

Mar 25, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Feb 11, 2025, 9:20 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 4, 2025, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 15, 2025, 2:15 PM EST - 1 year ago

Corvus Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Corvus Pharmaceuticals Slides: FY 2025

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Press release: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Slides: Study Update

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Sep 10, 2024, 12:00 PM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings release: Q2 2024

Aug 6, 2024, 4:01 PM EDT - 2 years ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Corvus Pharmaceuticals Registration statement: Registration Filing

Aug 1, 2024, 8:30 AM EDT - 2 years ago

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Jul 31, 2024, 8:30 AM EDT - 2 years ago

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Jun 5, 2024, 3:00 PM EDT - 2 years ago

Corvus Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2024

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Quarterly report: Q1 2024

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings release: Q1 2024

May 6, 2024, 4:01 PM EDT - 2 years ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024